Rating of The Day: Buy Rating Was Given to Imprimis Pharmaceuticals (NASDAQ:IMMY) By a Broker

November 28, 2016 - By Richard Conner

Rating of The Day: Buy Rating Was Given to Imprimis Pharmaceuticals (NASDAQ:IMMY) By a Broker

Why Rodman & Renshaw Gives Imprimis Pharmaceuticals (NASDAQ:IMMY) $5.00 Price Target

The financial firm Rodman & Renshaw has initiated coverage on Imprimis Pharmaceuticals (NASDAQ:IMMY)‘s stock, rating it a Buy while setting the PT at $5.00.

About 55,469 shares traded hands. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) has declined 34.42% since April 25, 2016 and is downtrending. It has underperformed by 40.44% the S&P500.

Analysts await Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) to report earnings on March, 22.

Insitutional Activity: The institutional sentiment increased to 5.5 in 2016 Q2. Its up 4.30, from 1.2 in 2016Q1. The ratio is positive, as 3 funds sold all Imprimis Pharmaceuticals Inc shares owned while 2 reduced positions. 1 funds bought stakes while 5 increased positions. They now own 1.66 million shares or 37.14% less from 2.64 million shares in 2016Q1.

The New York-based Berson & Corrado Investment Advisors Limited Liability Corporation has invested 0.08% in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY). Geode Cap Mngmt Limited has 17,570 shares for 0% of their US portfolio. Marathon Asset L P owns 833,333 shares or 0.17% of their US portfolio. Pnc Group has 0% invested in the company for 2,000 shares. Creative Planning last reported 750 shares in the company. Blackrock Fund Advisors last reported 0% of its portfolio in the stock. Vanguard Gp has 0% invested in the company for 168,584 shares. Northern Trust Corporation has 43,667 shares for 0% of their US portfolio. Marathon Cap Management last reported 25,000 shares in the company. Bank Of America De accumulated 17,797 shares or 0% of the stock. Manufacturers Life Ins The accumulated 0% or 169 shares. Tower Capital Limited Liability Co (Trc) has 548 shares for 0% of their US portfolio. Blackrock Invest Management Limited Liability Company holds 1,966 shares or 0% of its portfolio. Bard Associates holds 65,500 shares or 0.13% of its portfolio. Moreover, Granite Invest Ltd Liability Com has 0.05% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 155,190 shares.

Imprimis Pharmaceuticals, Inc. is engaged in the development, production and dispensing of compounded pharmaceuticals. The company has a market cap of $38.52 million. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. It currently has negative earnings. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases.

According to Zacks Investment Research, “Imprimis Pharmaceuticals, Inc. is a pharmaceutical company focused on its proprietary ophthalmology and urology drug formulations. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis.”

IMMY Company Profile

Imprimis Pharmaceuticals, Inc. (Imprimis), incorporated on January 11, 2006, is engaged in the development, production and dispensing of compounded pharmaceuticals. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Firm is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Firm also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas, including oncology, autoimmunity, chronic infectious diseases and endocrine and metabolic diseases.

More important recent Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) news were published by: Prnewswire.com which released: “Imprimis Pharmaceuticals Strengthens Senior Leadership Team with Key Hires in …” on August 15, 2016, also Prnewswire.com published article titled: “Imprimis Pharmaceuticals Announces Availability of Lower-Cost Option for the …”, Prnewswire.com published: “Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to …” on September 06, 2016. More interesting news about Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) was released by: Prnewswire.com and their article: “Imprimis Pharmaceuticals Announces Preliminary Revenue for Third Quarter 2015” with publication date: October 20, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>